Skip to main content
. Author manuscript; available in PMC: 2016 Mar 16.
Published in final edited form as: Clin Cancer Res. 2015 Nov 6;22(6):1325–1329. doi: 10.1158/1078-0432.CCR-15-1588

Figure 2.

Figure 2

Locations of the SMO mutations known to confer resistance through in vitro studies were identified in the BCCs of the study patients. The locations of these mutations within the SMO protein are shown on the left. Mutations Q476 and D473 are within the drug-binding pocket of sonidegib. Mutations S533 and W535 likely cause conformational change in SMO rendering the drug-binding pocket inaccessible to the sonidegib. The chemical structures of sonidegib and vismodegib are shown on the right for comparison.